U.S., April 7 -- ClinicalTrials.gov registry received information related to the study (NCT07513129) titled 'A Phase 1 Study Of Venetoclax, Dexamethasone, Bortezomib, And Daratumumab (VDBD) For Adolescent And Young Adult Patients With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And Lymphomas' on March 30.
Brief Summary: This is an open-label, single institution, Phase 1 study of Venetoclax, Dexamethasone, Bortezomib, and Daratumumab for adolescent and young adult participants with relapsed or refractory T-ALL or T-LBL
Study Start Date: Sept. 01, 2026
Study Type: INTERVENTIONAL
Condition:
T-cell Acute Lymphoblastic Leukemia
Lymphoma
Intervention:
DRUG: Venetoclax
Given by mouth
DRUG: Dexamethasone
Given by mouth or I...